Diphtheria: MSF warns of treatment shortages as Nigeria records over 1,100 deaths
The outbreak has caused 28,151 confirmed diphtheria infections and 1,126 deaths in Nigeria in 2026, according to a report citing NCDC data. Those figures were recorded as of 7 November. The scale matters because the outbreak is still spreading, and shortages of antitoxin are putting treatment of severely ill patients at risk. The same report counted 37,529 suspected cases. It said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas. Kano had the largest reported burden, with 12,008 confirmed cases, about 43 per cent of the national total. The figures are higher than those in MSF’s statement, which used NCDC statistics from 9 August and reported 406 deaths for 2026. The reports cover different periods, and later figures may reflect surveillance updates. MSF says medicine supplies are dangerously low and is urging authorities and partners to secure and distribute more antitoxin and vaccines.
How many confirmed diphtheria cases and deaths has Nigeria reported, and how widely has the outbreak spread?
The outbreak has caused 28,151 confirmed diphtheria infections and 1,126 deaths in Nigeria in 2026, according to a report citing NCDC data. Those figures were recorded as of 7 November. The scale matters because the outbreak is still spreading, and shortages of antitoxin are putting treatment of severely ill patients at risk.
The same report counted 37,529 suspected cases. It said the outbreak had affected 26 states and the Federal Capital Territory, covering 361 local government areas. Kano had the largest reported burden, with 12,008 confirmed cases, about 43 per cent of the national total.
The figures are higher than those in MSF’s statement, which used NCDC statistics from 9 August and reported 406 deaths for 2026. The reports cover different periods, and later figures may reflect surveillance updates. MSF says medicine supplies are dangerously low and is urging authorities and partners to secure and distribute more antitoxin and vaccines.
What is diphtheria antitoxin, and what does it do?
Diphtheria antitoxin, or DAT, is a medicine used to neutralise diphtheria toxin circulating in a patient’s bloodstream. That toxin can cause serious complications, so antitoxin is a lifesaving part of treatment. MSF says supplies are dangerously low in Nigeria, raising concern that teams may not be able to treat some severely ill patients.
The key mechanism is that antitoxin binds to and neutralises toxin in the blood. According to the WHO, antibiotics have a different job: they help eliminate the bacteria and reduce transmission. The medicines therefore address different parts of the illness. Antitoxin cannot reverse damage after toxin has entered body cells, which is why early administration matters.
MSF says limited global production and inconsistent availability have made adequate supplies difficult for treatment facilities to obtain. The organisation is calling on authorities, donors and international partners to secure additional medicines and vaccines, clear them through ports promptly and improve distribution to affected communities. The article does not identify which facilities have run out.
Why are health teams struggling to get enough antitoxin?
Health teams are struggling to get enough diphtheria antitoxin because global production is limited and supplies are not consistently available. MSF says these conditions have left treatment facilities struggling to obtain adequate amounts. The shortage matters because antitoxin is used to neutralise the toxin that can cause potentially fatal complications.
In Nigeria, MSF’s Medical Coordinator, David Kizito, warned that stocks were dangerously low and teams risked being unable to treat children as the outbreak continued. MSF called on federal and state authorities, donors and international partners to secure more medicines and vaccines. It also urged them to ensure timely clearance at ports and better distribution to affected communities.
The article does not identify which facilities had exhausted stocks, how many patients missed treatment, or whether any deaths were directly caused by shortages. It also does not say how much antitoxin reached Katsina after an earlier government intervention. MSF’s warning points to the need for additional supplies to reach treatment facilities in time, but the article gives no delivery timetable.
What can happen to a patient if antitoxin is delayed or unavailable?
Diphtheria can cause a thick membrane in the throat that sometimes obstructs breathing. Severe infections can also damage the heart, nerves and kidneys. Antitoxin is intended to neutralise toxin circulating in the bloodstream before it causes further harm. If the medicine is delayed or unavailable, a patient may be left without this protection at a critical point in treatment.
The WHO, as cited in the article, says early antitoxin administration is particularly important because it cannot reverse damage once the toxin has entered body cells. Antibiotics help eliminate the bacteria and reduce transmission, but they do not replace antitoxin’s role against circulating toxin. MSF warns that dangerously low stocks could compromise care for severely ill patients.
The article does not state how many patients have missed antitoxin or whether any deaths were directly caused by shortages. In Katsina, MSF managed 86 cases from 26 October to 12 November, including 70 classified as severe. The organisation is calling for more medicines and improved distribution, but it did not report whether planned additional supplies had arrived.
How large is the vaccine shortfall in Zamfara, and how many patients there had not been vaccinated?
The article provides no figure for a diphtheria vaccine shortfall in Zamfara and does not say how many patients there had not been vaccinated. It would therefore be inaccurate to give a number for either part of the question from this report. The article discusses the wider Nigerian outbreak and reports some state-level details for Kano and Katsina.
For Katsina, MSF said it managed 86 diphtheria cases between 26 October and 12 November. Seventy were classified as severe and 16 as non-severe. It also said teams reached 1,315 contacts through surveillance and contact tracing; 1,301 received vaccinations and 1,311 received preventive antibiotics. These are Katsina figures and do not describe Zamfara.
Nationally, the report cited 28,151 confirmed infections as of 7 November 2026 and said the outbreak had affected 26 states and the Federal Capital Territory. It noted that children who are unvaccinated or have not received all recommended vaccine doses are particularly affected. But it gives no Zamfara-specific vaccine supply, patient vaccination, or case breakdown.
Why must antitoxin be given early, and how is its role different from antibiotics?
Early antitoxin matters because diphtheria toxin can cause serious complications, and antitoxin cannot reverse damage once the toxin has entered body cells. Its role is to neutralise toxin circulating in the bloodstream. Delaying it can therefore mean missing the point at which it can act against toxin that is still circulating.
The WHO says antibiotics perform a different task: they help eliminate the bacteria and reduce transmission. In other words, antitoxin targets the toxin, while antibiotics target the bacteria. The two treatments are not interchangeable. MSF warns that low antitoxin supplies could compromise treatment for severely ill patients as Nigeria’s outbreak continues.
The report does not state how many patients have been unable to get antitoxin or whether any deaths were directly linked to shortages. It says limited global production and inconsistent availability are making supplies difficult to obtain. MSF is urging authorities and partners to secure more medicines and ensure they reach affected communities promptly, because timing is central to antitoxin’s role.
How does vaccination help protect people and slow the spread of diphtheria?
Diphtheria is vaccine-preventable, and the article says the outbreak is particularly affecting children who are unvaccinated or have not received all recommended vaccine doses. Vaccination matters both for individual protection and for reducing the number of people who can become ill during an outbreak. The article calls for authorities and partners to secure additional vaccines as well as medicines.
In general, vaccines train the immune system to recognise a disease, helping the body respond if it encounters the infection later. That is general background; the article does not explain the immune process in detail. It reports that MSF teams in Katsina reached 1,315 contacts, of whom 1,301 received vaccinations, as part of surveillance and contact-tracing activities.
Nigeria’s outbreak had produced 28,151 confirmed cases by 7 November 2026 and affected 26 states and the Federal Capital Territory. The report does not quantify how much vaccination has reduced transmission. MSF is urging timely vaccine supply and distribution to affected communities, while the figures underscore the importance of reaching people who are unvaccinated or missing doses.
This brief was written by AI from the original reporting and checked by other models. Names, figures and quotes come from the source; read it for full context.
Read more in the JupiteX app
Pulse is free. New stories every 4 hours, each one broken into the questions that explain it.
Or read more news on the web